ArticleFrontiers in immunology2025
Exosomal miRNA-148b/301a/423 cluster predicts pneumonitis risk in NSCLC with concurrent radiotherapy with immunotherapy via PTPN14-YAP signaling: a retrospective cohort study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MicroRNA-Mediated Regulation of Ionizing Radiation Responses: Mechanisms and Advances in Clinical Translation.Current issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radiotherapy (RT) combined with Immune checkpoint inhibitors (ICIs) significantly improve outcomes in non-small cell lung cancer (NSCLC), yet this combination amplifies treatment-related pneumonitis risk. The real-world incidence, predictive biomarkers, and underlying pathogenesis of RT-ICI-associated pneumonitis remain inadequately defined. Methods: We conducted a retrospective cohort study using electronic health records from 21,671 NSCLC patients treated with thoracic RT, categorized into RT-ICI (n=8,744) and RT-nonICI (n=12,927) groups after 1:1 propensity score matching. Pneumonitis was diagnosed via clinical/imaging criteria and infection exclusion. Incidence of pneumonitis was evaluated using propensity score-matched analysis, Kaplan-Meier curves, and Cox regression models. Subgroup analyses were performed across demographic and clinical variables. Serum exosomes from 20 patients underwent miRNA sequencing. LASSO regression for biomarker modeling, single-cell RNA-seq analysis and single-sample gene set enrichment analysis for function enrichment, then validated Results: The incidence of pneumonitis was significantly higher in the RT-ICI group (28.9%) compared to the RT-nonICI group (10.0%) (hazard ratio [HR]=2.86; 95% confidence interval [CI], 2.43-3.29; P<0.001). This elevated risk persisted across age, sex, BMI, comorbidities, and autoimmune status. We identified a serum exosomal miRNA cluster (miR-148b-3p, miR-301a-3p, miR-423-3p) predictive of pneumonitis and poor survival. These miRNAs directly co-target PTPN14, and crosstalk with fibrosis via TNF signal at the single-cell level. Then we validated the miRNA cluster suppressed PTPN14, activating YAP signal to promote EMT in pulmonary epithelial cell lines. Conclusions: RT-ICI therapy significantly increases pneumonitis risk in NSCLC, especially in autoimmune comorbidities. A serum exosomal miRNA cluster (miR-148b-3p/301a-3p/423-3p) enables early pneumonitis prediction and prognosis assessment, offering novel targets for prevention and monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.